Enterothelin emerges as lead candidate from Epiendo and Alveolix’s ulcerative colitis collaboration
June 5, 2024
Epiendo Pharmaceuticals ehf and Alveolix AG have achieved significant milestones in their collaboration to advance the treatment of ulcerative colitis.